Dr. Long on the Rationale for the Phase 3 COMBI-i Trial in BRAF V600–Mutant Melanoma

Georgina Long, BSc, PhD, MBBS, FRACP, co-medical director, Melanoma Institute Australia (MIA), chair of Melanoma Medical Oncology and Translational Research, MIA and Royal North Shore Hospital, University of Sydney, discusses the rationale for the phase 3 COMBI-i trial in BRAF V600¬–mutant melanoma.